Evolving paradigms for successful molecular imaging of medullary thyroid carcinoma
- 690 Downloads
Medullary thyroid cancer (MTC) is a rare, neuroendocrine tumour (NET) of parafollicular C cells comprising 5–8% of all thyroid cancers with variable biological behaviour and prognosis . Overall mean survival in MTC is 75–85% at 10 years [1, 2, 3]. Management of both hereditary (20–30%) and sporadic MTC is challenging due to early cervical lymph node metastases occurring in 50% of patients and distant metastases to the liver, lung and bones being found in 10–20% at diagnosis [1, 3]. MTC secretes several neuroendocrine peptides, of which calcitonin (Ct) and less-specific carcinoembryonic antigen (CEA) are useful tumour markers for diagnosis, surveillance and prognosis. Yet despite the high sensitivity of an elevated serum Ct value as a predictor of disease presence, MTC is an elusive and notoriously problematic tumour to image [1, 3]. Anatomy-based imaging with CT and MRI has exhibited limited sensitivity due to the frequent small size of the metastatic deposits. Although a variety of specific and nonspecific scintigraphic techniques such as 201Tl, 99mTc-sestamibi, 99mTc-tetrofosmin, 131I/123I-metaiodobenzylguanidine, 99mTc-(V)dimercaptosuccinic acid (DMSA), and 111In-octreotide have been used to image MTC, none has emerged as the imaging technique of choice [4, 5]. This raises the question as to why we have been unable to successfully image MTC.
The rarity of MTC implies that no single centre can collect a sufficient number of cases, and to date there have been no large, cooperative studies to establish optimal imaging protocols. It has become apparent that MTCs are a heterogeneous group of neoplasms, and the biological behaviour of one MTC may differ significantly from that of another. Imaging approaches that have proven successful, for example using 18F-fluorodeoxyglucose (FDG) PET/CT in lymphoma and solid cancers and 111In-octreotide for somatostatin receptor scintigraphy (SRS) in carcinoids, may be too simplistic an imaging approach for MTC, which often appears intermediate in biological behaviour between more aggressive neoplasms characterized by high Ki-67 indices, and hormonally active NETs in which FDG PET has limited value.
Genetic testing provides a valuable insight into the phenotypic expression of MTC. Genetic mapping has confirmed the central role of germline mutations of the rearranged during transfection (RET) protooncogene in the pathogenesis of inherited MTC and has shown that somatic RET mutations occur in 50–60% of patients with sporadic MTC, and there have been advances in our understanding of how activated RET tyrosine kinase signalling pathways affect tumour growth and angiogenesis [1, 6, 7, 8]. Insights from genetic testing allow informed management decisions. As an example, the dilemma of the timing of prophylactic thyroidectomy in multiple endocrine neoplasia type 2 (MEN2), an autosomal dominant syndrome with near-complete penetrance in C cell hyperplasia and evolution to MTC, has been somewhat clarified with the availability of risk stratification guidelines based upon mutation-specific classifications [9, 10]. The American Thyroid Association (ATA) risk level D, including all MEN2B mutations, predicts an aggressive disease course with recommended early thyroidectomy before the age of 1 year. Conversely, for risk level A mutations, surgery may be safely delayed beyond the age of 5 years if basal and stimulated Ct levels remain normal.
In the last decade the success of FDG PET/CT in oncology imaging, and the increasing availability of hybrid PET/CT and SPECT/CT cameras, has fuelled intense interest in the development of multiple alternative single-photon-emitting somatostatin analogues and non-FDG positron-emitting radiopharmaceuticals, which demonstrate increased sensitivity for imaging MTC and NETs . Total thyroidectomy with prophylactic central neck dissection, with or without lateral compartment dissection of lymph nodes is potentially curative in 60% of N0 patients, but in N1 patients cure rates fall to around 10% . To our knowledge, there are no studies of the use of either PET/CT or SPECT/CT for preoperative MTC staging, although unlike radioiodine imaging in well-differentiated thyroid cancer, total thyroidectomy is not a prerequisite for successful imaging of in-situ or locoregional metastatic disease in MTC. As recurrence rates of MTC approach 50%, patients should be monitored after initial surgical management with Ct and CEA levels, including calculation of doubling times [1, 3, 9, 11]. Should tumour biomarkers indicate persistent or recurrent disease, accurate restaging of MTC is crucial in subsequent management, whether to pursue a surgically based approach in an attempt to control locoregional disease, or to identify the best time to switch to systemic therapy for distant metastatic disease.
The first reported use of FDG PET in MTC was in 1997 where tumour was localized in 7/8 patients (88%) , while in a larger group of 85 patients with histological confirmation, FDG PET demonstrated a sensitivity (78%) equal to that of MRI (82%), and superior to those of CT (50%), DMSA (33%) and somatostatin scintigraphy (25%) . Two studies showed that FDG PET/CT outperforms CT and MRI for the detection of neck and mediastinal disease, but is inferior to CT for the detection of lung and liver metastases, and to MRI for the identification of metastases to bone [17, 18]. Three studies have examined serum Ct levels and the likelihood of a positive FDG PET scan. In general a significant gain in sensitivity is seen at a threshold plasma Ct level of >1,000 pg/ml. Conversely, sensitivity is low at 0–37% when the plasma Ct level is <500 pg/ml [19, 20, 21]. One study showed the prognostic value of FDG PET with 6 of 11 PET-positive patients (55%) succumbing to their disease, and 13 of 14 PET-negative patients (93%) remaining disease-free with an average follow-up of 44 months . From these few studies it appears that FDG PET and PET/CT have an overall sensitivity in the range 47–79% with a trend to lower disease detection rates in more recent studies . Although the use of FDG has been a significant step forward in the detection of MTC recurrences, it may be the optimal imaging technique for only a subset of patients with MTC.
In a recent study, Luster et al.  found that no patient with a basal Ct level less than 60 pg/ml was truly positive for MTC on FDOPA PET/CT, and conversely that no patient with a basal Ct level more than 120 pg/ml was truly negative for MTC on PET/CT. They reported a sensitivity and specificity of 100% for FDOPA PET/CT in patients with a basal Ct level of ≥150 pg/ml. The findings of this study were in line with the 2009 American Thyroid Association MTC management guidelines  that suggest additional imaging procedures (e.g. FDOPA PET/CT) should be applied to supplement cervical ultrasonography in any patient with a postsurgical basal Ct level of ≥150 pg/ml. Similar results were also obtained in a very recent prospective study by Kauhanen et al.  who compared FDOPA and FDG PET/CT with multidetector CT (MDCT) and MRI in recurrent or persistent MTC. They concluded that FDOPA PET/CT and FDG PET/CT were complementary in patients with an unstable Ct level; however, in patients with an unstable CEA doubling time, FDG PET/CT seemed to be the preferred option. In this study, MRI proved to be a sensitive method for detection of occult MTC lesions, but it mainly suffered from inadequate specificity as it had the highest rate of false-positive lesions. It is worth noting that in a very recent ongoing study, Marzola et al.  evaluated 18 MTC patients with rapidly increasing serum Ct levels and negative conventional imaging after first treatment, comparing the results of FDG PET/CT and those of FDOPA PET/CT. These authors also found that FDG and FDOPA can play a complementary role, but they also reported that in three patients FDOPA was the only positive examination for solitary local relapse in the thyroid bed and that prompt reoperation led to normalization of the serum Ct levels in two patients. So the authors concluded that FDOPA PET/CT seems able to detect local MTC relapse early in a phase when the patient can be successfully cured by reoperation.
While most studies have shown clear superiority of FDOPA PET/CT over FDG PET/CT [27, 30, 35], it is assumed that the combination of the two radiopharmaceuticals would probably provide the highest diagnostic sensitivity and specificity [34, 35], in particular in patients with short (<6 months) Ct doubling times . FDOPA seems to provide more reliable prognostic information whereas FDG allows prognostic evaluation .
To our knowledge there is only a single published study specifically aimed at assessing the role of PET/CT with 68Ga-DOTA peptides in MTC. The authors compared the accuracy of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in 18 patients previously radically treated for MTC and showing increasing serum Ct levels . Both tracers showed similar suboptimal sensitivity values (72.2% for DOTATATE, 77.8% for FDG) for the detection of recurrent MTC. The observation that 68Ga-DOTA peptide PET/CT may be useful in MTC patients but may fail to delineate either the whole tumour burden or tumour lesions with variable expression of somatostatin receptors has also been shown in single MTC cases described in the literature in the context of a large population of patients with NET with the location of the primary tumour other than in the thyroid. For example, of the only two patients with MTC among a population of 51 patients with NET with a nonthyroid primary, DOTATATE uptake was evident in one of the patients with an intermediate differentiation grade and absent in the other patient with a low differentiation grade . The most relevant factor limiting MTC imaging with 68Ga-DOTA peptides is the well-known lower incidence, variable density and an inhomogeneous pattern of somatostatin receptor expression on MTC cells [38, 39]. Therefore the effective clinical impact of 68Ga-DOTA peptides in the diagnosis of MTC lesions remains controversial. However, it is important to underline that the confirmation of somatostatin receptors on MTC lesions in patients positive on 68Ga-DOTA peptide PET may provide the indication to start radionuclide-targeted therapy that has been reported to be associated with a long-term survival benefit . 68Ga-DOTA peptide PET positivity would suggest an increased likelihood of the efficacy of 177Lu- or 90Y-labelled somatostatin analogue radionuclide therapy.
11C-methionine PET has also been used to image MTC, although the reported lesion-based sensitivity of 73% is similar to that of FDG PET (80%), and thus provides no clear advantage over FDG PET .
Unlike initial surgical management, reoperation for recurrent MTC rarely normalizes serum Ct levels  and the availability of more sensitive radiopharmaceuticals for localizing distant metastatic spread would reduce morbidity related to furtive surgical management. The lack of efficacy of external beam radiation treatment [3, 43, 44], the low chemotherapy response rates of only 10–20% [1, 45, 46], and the modest impact of 131I- or 90Y-labelled targeted radionuclide therapies with response rates of approximately 30% , provide great impetus for studies of novel multikinase inhibitors as new approaches to therapy [45, 46]. The present clinical guidelines recommend that kinase inhibitors are the preferred best “current practice” therapy for inoperable, progressive MTC and should be investigated in clinical trials [6, 9, 11]. These small-molecule inhibitors, which include vandetanib and sorafenib, block ATP at catalytic sites in the RET tyrosine kinase activation pathway and have been found to have modest efficacy for stabilization of aggressive disease [6, 7, 8, 47]. Vandetanib is the first kinase inhibitor, approved by the FDA in April 2011 [6, 48], and is generally well tolerated although cardiovascular, dermatological, endocrine and gastrointestinal toxicities have been encountered .
Eligibility for trials of kinase inhibitors is currently based on demonstrable macroscopic disease amenable to RECIST anatomical response assessment . However, some patients with elevated and rapidly rising Ct levels, in whom the source(s) cannot be identified will fail to meet inclusion criteria. Reliance on decreasing tumour size as a marker of response fails to account for the presence of amyloid sheets, found in 60–80% of MTC tumours, which may persist despite a therapeutic response, so that drug efficacy is underestimated [1, 8, 43]. Recently published PERCIST criteria highlight the importance of including metabolic response criteria into clinical trials of anticancer drugs, as these are more closely correlated with therapeutic response and survival . Metabolic response criteria using FDG PET in mouse models for predicting early therapeutic efficacy of vandetanib have been reported . Resistance to kinase inhibitors, recognized as arising from tumour activation of alternative signalling pathways , appears to account for decreased drug effect(s), and molecular imaging techniques may more reliably distinguish responders and nonresponders.
Management of MTC requires highly accurate staging and restaging imaging techniques to optimize treatment strategies. For determination of a surveillance strategy for both sporadic and hereditary MTC, we now have the toolset to characterize tumours. Genetic testing, histological differentiation and grade (Ki-67 indices) , tumour secretogogues, and Ct and CEA levels and doubling times [1, 9] can be used to develop a phenotype model to tailor individualized treatment and imaging surveillance. Customized imaging approaches will determine which radiopharmaceutical (FDG or non-FDG, especially FDOPA) is optimal for PET imaging of a given patient with MTC. Conversely, these imaging studies will provide unique information on individual tumour phenotype expression, including lack of tumour avidity, which may reveal as much about tumour behaviour and prognosis as a positive study.
Thus, our early experience suggests that molecular imaging will play an increasingly important role in the development of successful imaging and treatment strategies in MTC.
Conflicts of interest
- 18.Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92:4590–7.PubMedCrossRefGoogle Scholar
- 22.Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010;12:547–53.PubMedCrossRefGoogle Scholar
- 31.Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. Eur J Surg Oncol. 2010;36:414–21.PubMedCrossRefGoogle Scholar
- 36.Marzola MC, Ferdeghini M, Rampin L, Banti L, Grassetto G, Cittadin S, et al. Sequential 18F-FDG and 18-F-DOPA PET/CT in recurrent medullary thyroid cancer (MTC). J Nucl Med. 2010;51 Suppl 2:71.Google Scholar
- 43.Tai D, Poon D. Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. J Oncol. 2011;2011:pii 398564Google Scholar
- 44.Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775–83.PubMedCrossRefGoogle Scholar